The Role of Immunosuppression on Postoperative Outcomes in Facial Fracture Repair.

Hänel W Eberly,Andrew J Rothka,Bao Y Sciscent,Jessyka G Lighthall
{"title":"The Role of Immunosuppression on Postoperative Outcomes in Facial Fracture Repair.","authors":"Hänel W Eberly,Andrew J Rothka,Bao Y Sciscent,Jessyka G Lighthall","doi":"10.1177/01455613241275257","DOIUrl":null,"url":null,"abstract":"Objectives: To assess postoperative outcomes in immunosuppressed patients with facial fractures. Methods: TriNetX, a large de-identified health research database, was utilized to compare outcomes within 30 days of treatment between immunosuppressed and immunocompetent patients with facial fractures. Subgroup analysis was conducted based on use of immunosuppressive therapy, human immunodeficiency virus (HIV) status, diabetes, and chronic kidney disease (CKD). Results: Nine thousand four hundred seventy-five patients were identified. On subgroup analysis, 555 patients were on immunosuppressants, 429 patients had HIV, 619 patients had CKD, 1322 patients with liver disease, and 3133 had diabetes. Immunosuppressed patients more frequently experienced postoperative infections [odds ratio (OR) 1.37 (1.9-1.54), P < .001], thromboembolic events [OR 1.71 (1.33-2.20), P < .001], hemorrhage [OR 1.46 (1.10-1.92), P = .0087], hospital readmission [OR 1.36 (1.28-1.44), P < .001], subsequent emergency department encounters [OR 1.08 (1.01-1.15), P = .0249], and wound disruptions [OR 1.52 (1.17-1.97), P = .0017]. Analyses comparing outcomes by immunosuppression type found increased rates of infection [OR 1.59 (1.25-2.01), P < .001], thromboembolic events [OR 1.56 (1.07-2.26), P = .0196], wound disruption [OR 1.57 (1.03-2.39), P = .0357], and hospital readmission [OR 1.28 (1.16-1.42), P < .001] in diabetic patients. Patients with CKD [OR 1.7 (1-2.90), P = .0478] had higher rates of infection [OR 2.02 (1.18-3.46), P = .0092] and readmission [OR 1.43 (1.14-1.79), P = .0017]. Patients with liver disease had higher rates of infection [OR 1.54 (1.07-2.23), P = .0210], thromboembolic events [OR 2.84 (1.37-5.87), P = .0033], and readmission [OR 2.14 (1.83-2.51), P < .001]. No significant differences were seen between groups for HIV patients. Conclusions: Immunosuppressed patients with facial trauma have a higher prevalence of postoperative complications compared to immunocompetent patients. Diabetics had a higher prevalence of most complications while patients with CKD and liver disease had higher rates of infections. Surgeons may consider measures to decrease postoperative risk in these patients and to provide preoperative patient counseling.","PeriodicalId":93984,"journal":{"name":"Ear, nose, & throat journal","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2024-09-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Ear, nose, & throat journal","FirstCategoryId":"0","ListUrlMain":"https://doi.org/10.1177/01455613241275257","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Objectives: To assess postoperative outcomes in immunosuppressed patients with facial fractures. Methods: TriNetX, a large de-identified health research database, was utilized to compare outcomes within 30 days of treatment between immunosuppressed and immunocompetent patients with facial fractures. Subgroup analysis was conducted based on use of immunosuppressive therapy, human immunodeficiency virus (HIV) status, diabetes, and chronic kidney disease (CKD). Results: Nine thousand four hundred seventy-five patients were identified. On subgroup analysis, 555 patients were on immunosuppressants, 429 patients had HIV, 619 patients had CKD, 1322 patients with liver disease, and 3133 had diabetes. Immunosuppressed patients more frequently experienced postoperative infections [odds ratio (OR) 1.37 (1.9-1.54), P < .001], thromboembolic events [OR 1.71 (1.33-2.20), P < .001], hemorrhage [OR 1.46 (1.10-1.92), P = .0087], hospital readmission [OR 1.36 (1.28-1.44), P < .001], subsequent emergency department encounters [OR 1.08 (1.01-1.15), P = .0249], and wound disruptions [OR 1.52 (1.17-1.97), P = .0017]. Analyses comparing outcomes by immunosuppression type found increased rates of infection [OR 1.59 (1.25-2.01), P < .001], thromboembolic events [OR 1.56 (1.07-2.26), P = .0196], wound disruption [OR 1.57 (1.03-2.39), P = .0357], and hospital readmission [OR 1.28 (1.16-1.42), P < .001] in diabetic patients. Patients with CKD [OR 1.7 (1-2.90), P = .0478] had higher rates of infection [OR 2.02 (1.18-3.46), P = .0092] and readmission [OR 1.43 (1.14-1.79), P = .0017]. Patients with liver disease had higher rates of infection [OR 1.54 (1.07-2.23), P = .0210], thromboembolic events [OR 2.84 (1.37-5.87), P = .0033], and readmission [OR 2.14 (1.83-2.51), P < .001]. No significant differences were seen between groups for HIV patients. Conclusions: Immunosuppressed patients with facial trauma have a higher prevalence of postoperative complications compared to immunocompetent patients. Diabetics had a higher prevalence of most complications while patients with CKD and liver disease had higher rates of infections. Surgeons may consider measures to decrease postoperative risk in these patients and to provide preoperative patient counseling.
免疫抑制对面部骨折修复术后效果的影响
目的:评估面部骨折免疫抑制患者的术后效果:评估面部骨折免疫抑制患者的术后效果。方法:利用大型去标识化健康研究数据库 TriNetX 比较面部骨折免疫抑制患者和免疫功能正常患者在治疗后 30 天内的疗效。根据免疫抑制疗法的使用情况、人类免疫缺陷病毒(HIV)状态、糖尿病和慢性肾病(CKD)进行了分组分析。结果共发现 9 475 名患者。经分组分析,555 名患者正在服用免疫抑制剂,429 名患者感染了艾滋病毒,619 名患者患有慢性肾脏病,1322 名患者患有肝病,3133 名患者患有糖尿病。免疫抑制患者更常发生术后感染[比值比 (OR) 1.37 (1.9-1.54),P < .001]、血栓栓塞事件[OR 1.71 (1.33-2.20),P < .001]、出血[OR 1.46 (1.10-1.92),P = .0087]。92),P = .0087]、再入院[OR 1.36(1.28-1.44),P < .001]、后续急诊就诊[OR 1.08(1.01-1.15),P = .0249]和伤口破坏[OR 1.52(1.17-1.97),P = .0017]。通过分析比较免疫抑制类型的结果发现,糖尿病患者的感染率[OR 1.59 (1.25-2.01),P < .001]、血栓栓塞事件[OR 1.56 (1.07-2.26),P = .0196]、伤口破坏[OR 1.57 (1.03-2.39),P = .0357]和再入院率[OR 1.28 (1.16-1.42),P < .001]均有所增加。患有慢性肾脏病的患者[OR 1.7 (1-2.90),P = .0478]感染率[OR 2.02 (1.18-3.46),P = .0092]和再入院率[OR 1.43 (1.14-1.79),P = .0017]更高。肝病患者的感染率[OR 1.54 (1.07-2.23),P = .0210]、血栓栓塞事件[OR 2.84 (1.37-5.87),P = .0033]和再入院率[OR 2.14 (1.83-2.51),P < .001]更高。HIV 患者的组间差异不明显。结论与免疫功能正常的患者相比,面部创伤的免疫抑制患者术后并发症发生率更高。糖尿病患者大多数并发症的发生率较高,而患有慢性肾功能衰竭和肝病的患者感染率较高。外科医生可考虑采取措施降低这些患者的术后风险,并为患者提供术前咨询。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信